Figure 1:

Development of a residue-specific, patient-specific MHC-II presentation score. A graphical representation (A) of the Best Rank (BR) presentation score for a residue, (B) MHC-II genetic diversity in the population, and (C) of the the Patient Harmonic-mean Best Rank Class II (PHBR-II) presentation score. (D) An experimental schematic of the MS-based validation of the PHBR-II score. HLA-DR MS data from 7 donors was used to validate the PHBR-II score. (E) ROC AUC curves showing the accuracy of the PHBR-II for classifying the extracellular presentation of a residue by a patient’s HLA-DR genes for 7 donors (colors) and for all donors combined (black). The aggregated PHBR-II presentation scores for the 7 donors expression HLA-DR alleles was compared to a sent of random residues for the same HLA-DR alleles. See also Figure S1, Figure S2 and Table S1.